Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

J. T. Vetto, M. Z. Papa, M. T. Lotze, A. E. Chang, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

In order to evaluate the efficacy of dexamethasone (dex) in reducing the toxicity of therapy with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) we treated six patients receiving this form of immunotherapy with intravenous (IV) dex, 4 mg every six hours. Compared with a control group of 27 patients not receiving dex with their immunotherapy, these corticosteroid-treated patients were able to tolerate the administration of more IL-2, yet experienced significantly less toxicity. Dyspnea, confusion, fever, mean peak serum creatinine, and bilirubin levels during treatment were significantly reduced in corticosteroid-treated patients, with a corresponding decrease in pruritis in this group as well. Overall weight gain was not different between groups, although a curtailment of weight gain temporally related to dex treatment was seen in some patients. Hematologic side effects, including anemia, eosinophilia, and thrombocytopenia, were not reduced by dex. These results suggest that dex can inhibit at least some of the toxic side effects of LAK cell and IL-2 therapy. Because of the concern that the therapeutic effect may also be abrogated, future studies combining corticosteroids with this form of immunotherapy should be undertaken with caution.

Original languageEnglish (US)
Pages (from-to)496-503
Number of pages8
JournalJournal of Clinical Oncology
Volume5
Issue number3
StatePublished - 1987
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Dexamethasone
Interleukin-2
Adrenal Cortex Hormones
Immunotherapy
Weight Gain
Poisons
Eosinophilia
Therapeutic Uses
Therapeutics
Pruritus
Bilirubin
Thrombocytopenia
Dyspnea
Anemia
Creatinine
Fever
Control Groups
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. / Vetto, J. T.; Papa, M. Z.; Lotze, M. T.; Chang, A. E.; Rosenberg, S. A.

In: Journal of Clinical Oncology, Vol. 5, No. 3, 1987, p. 496-503.

Research output: Contribution to journalArticle

Vetto, J. T. ; Papa, M. Z. ; Lotze, M. T. ; Chang, A. E. ; Rosenberg, S. A. / Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. In: Journal of Clinical Oncology. 1987 ; Vol. 5, No. 3. pp. 496-503.
@article{5b467cdfc1b5489dad938c73a462fa1c,
title = "Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids",
abstract = "In order to evaluate the efficacy of dexamethasone (dex) in reducing the toxicity of therapy with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) we treated six patients receiving this form of immunotherapy with intravenous (IV) dex, 4 mg every six hours. Compared with a control group of 27 patients not receiving dex with their immunotherapy, these corticosteroid-treated patients were able to tolerate the administration of more IL-2, yet experienced significantly less toxicity. Dyspnea, confusion, fever, mean peak serum creatinine, and bilirubin levels during treatment were significantly reduced in corticosteroid-treated patients, with a corresponding decrease in pruritis in this group as well. Overall weight gain was not different between groups, although a curtailment of weight gain temporally related to dex treatment was seen in some patients. Hematologic side effects, including anemia, eosinophilia, and thrombocytopenia, were not reduced by dex. These results suggest that dex can inhibit at least some of the toxic side effects of LAK cell and IL-2 therapy. Because of the concern that the therapeutic effect may also be abrogated, future studies combining corticosteroids with this form of immunotherapy should be undertaken with caution.",
author = "Vetto, {J. T.} and Papa, {M. Z.} and Lotze, {M. T.} and Chang, {A. E.} and Rosenberg, {S. A.}",
year = "1987",
language = "English (US)",
volume = "5",
pages = "496--503",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

AU - Vetto, J. T.

AU - Papa, M. Z.

AU - Lotze, M. T.

AU - Chang, A. E.

AU - Rosenberg, S. A.

PY - 1987

Y1 - 1987

N2 - In order to evaluate the efficacy of dexamethasone (dex) in reducing the toxicity of therapy with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) we treated six patients receiving this form of immunotherapy with intravenous (IV) dex, 4 mg every six hours. Compared with a control group of 27 patients not receiving dex with their immunotherapy, these corticosteroid-treated patients were able to tolerate the administration of more IL-2, yet experienced significantly less toxicity. Dyspnea, confusion, fever, mean peak serum creatinine, and bilirubin levels during treatment were significantly reduced in corticosteroid-treated patients, with a corresponding decrease in pruritis in this group as well. Overall weight gain was not different between groups, although a curtailment of weight gain temporally related to dex treatment was seen in some patients. Hematologic side effects, including anemia, eosinophilia, and thrombocytopenia, were not reduced by dex. These results suggest that dex can inhibit at least some of the toxic side effects of LAK cell and IL-2 therapy. Because of the concern that the therapeutic effect may also be abrogated, future studies combining corticosteroids with this form of immunotherapy should be undertaken with caution.

AB - In order to evaluate the efficacy of dexamethasone (dex) in reducing the toxicity of therapy with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) we treated six patients receiving this form of immunotherapy with intravenous (IV) dex, 4 mg every six hours. Compared with a control group of 27 patients not receiving dex with their immunotherapy, these corticosteroid-treated patients were able to tolerate the administration of more IL-2, yet experienced significantly less toxicity. Dyspnea, confusion, fever, mean peak serum creatinine, and bilirubin levels during treatment were significantly reduced in corticosteroid-treated patients, with a corresponding decrease in pruritis in this group as well. Overall weight gain was not different between groups, although a curtailment of weight gain temporally related to dex treatment was seen in some patients. Hematologic side effects, including anemia, eosinophilia, and thrombocytopenia, were not reduced by dex. These results suggest that dex can inhibit at least some of the toxic side effects of LAK cell and IL-2 therapy. Because of the concern that the therapeutic effect may also be abrogated, future studies combining corticosteroids with this form of immunotherapy should be undertaken with caution.

UR - http://www.scopus.com/inward/record.url?scp=0023134875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023134875&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 496

EP - 503

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -